These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26953659)

  • 1. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM; Amo-Salas M; Relea Calatayud F; Muñoz Sánchez Mdel M; Pena Pardo FJ; Jiménez Londoño GA; Álvarez Cabellos R; Espinosa Aunión R; Soriano Castrejón Á
    Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral heterogeneity in
    Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón Á; León Martín A; Relea Calatayud F; Muñoz Sánchez Mdel M; Cruz Mora MÁ; Jiménez Londoño GA; Espinosa Aunión R
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1309-18. PubMed ID: 24744045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.
    Garcia Vicente AM; Soriano Castrejón A; Amo-Salas M; Lopez Fidalgo JF; Muñoz Sanchez MM; Alvarez Cabellos R; Espinosa Aunion R; Muñoz Madero V
    Rev Esp Med Nucl Imagen Mol; 2016; 35(3):152-8. PubMed ID: 26522003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
    Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.